Discounted Cash Flow (DCF) Analysis Levered

CTI BioPharma Corp. (CTIC)

$ 2.565
-0.10 (-3.57%)
Stock DCF: 0.32 | 2.565 | overvalue

Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 57.4125.1526.293.35000000
Revenue (%)
Operating Cash Flow -76.68-39.30-39.82-27.82-42.20-3.41-1.37-0.55-0.22-0.09
Operating Cash Flow (%)
Capital Expenditure -0.14-0.05-0.03-0.01-0-0-0-0-0-0
Capital Expenditure (%)
Free Cash Flow -76.82-39.35-39.86-27.83-42.21-3.41-1.37-0.55-0.22-0.09

Weighted Average Cost Of Capital

Share price $ 2.565
Beta 0.676
Diluted Shares Outstanding 71.14
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 11.58%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.628
Total Debt 8.91
Total Equity 182.48
Total Capital 191.39
Debt Weighting 4.66
Equity Weighting 95.34
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 57.4125.1526.293.35000000
Operating Cash Flow -76.68-39.30-39.82-27.82-42.20-3.41-1.37-0.55-0.22-0.09
Capital Expenditure -0.14-0.05-0.03-0.01-0-0-0-0-0-0
Free Cash Flow -76.82-39.35-39.86-27.83-42.21-3.41-1.37-0.55-0.22-0.09
WACC
PV LFCF -3.25-1.25-0.48-0.18-0.07
SUM PV LFCF -5.22

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.95
Free cash flow (t + 1) -0.09
Terminal Value -4.62
Present Value of Terminal Value -3.63

Intrinsic Value

Enterprise Value -8.86
Net Debt -31.48
Equity Value 22.63
Shares Outstanding 71.14
Equity Value Per Share 0.32